MOUNTAIN VIEW, Calif., April 27, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, announced today that management is planning to present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 11, 2011 at 3:00 p.m. Pacific time at Encore at Wynn, Las Vegas, NV.
A live webcast of the presentation will be available on the company's website at . When accessing the webcast through the Conceptus site, select "Investors" then select "Events and Presentations." The archived replay will be available through May 27, 2011.
Notification of Inducement Grant of Stock Appreciation Rights
In connection with the hiring of Executive Vice President of Marketing Sam Trujillo at the beginning of the first quarter of 2011, the Company made an inducement grant of stock appreciation rights to Mr. Trujillo. These stock appreciation rights were granted without stockholder approval pursuant to NASDAQ Marketplace Rule 5635(a)(c)(4) and have the following terms: 125,000 stock appreciation rights, an exercise price of $14.30 per share (the closing price of the Company's common stock on the grant date of March 2, 2011), a seven-year term and a four-year vesting schedule structured with 12.5% of the SARs vesting on July 4, 2011, and the remainder of the SARs vesting monthly thereafter in equal amounts over the next 42 months of service with the company.
About the Essure® Procedure
The Essure procedure, FDA approved since 2002, is the first permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around and through the micro-inserts to prevent sperm from reaching the egg. Three months after the Essure procedure, a doctor is able to perform an Essure Confirmation Test to confirm that the inserts are properly placed and the fallopian tubes are fully blocked, giving the patient reliance on Essure for permanent birth control.
The Essure procedure is 99.95% effective based on one year of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor's office the cost to the patient may be as low as a simple co-pay. Essure has been proven and trusted by physicians since 2002, with more than 500,000 women worldwide having undergone the Essure procedure.
About Conceptus, Inc.
Conceptus, Inc. is a leader in the design, development, and marketing of innovative solutions in women's healthcare. The Company manufactures and markets the Essure procedure. The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East. The Company also promotes the GYNECARE THERMACHOICE® Uterine Balloon Therapy System by ETHICON™ Women's Health & Urology, a division of Ethicon, Inc., in U.S. OB/GYN physician offices.
The Conceptus, Inc. logo is available at
Please visit for more information on the Essure procedure. Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area.
© 2011 Conceptus, Inc -- All rights reserved. Conceptus, Essure and Your Family is Complete. Your Choice is Clear are registered trademarks and service marks of Conceptus, Inc.
CC-2766 27APR11F
CONTACT: Investor Relations and Public Relations Contact: Cindy Klimstra (650) 962-4032 cindy_klimstra@conceptus.com
